MR
Merck & Co.
MRK · NYSE
$147.48 -0.66% (-$0.98)
1M +14.84%
Market Cap $366.7B
P/E Ratio 115.58x
Div. Yield 2.26%
ROE 6.60%
Bulios Fair Price
$152.74
3.6% upside
Current Price
$147.48
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MRK is currently trading close to its fair value. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
21 /100
Expensive P/E 115.58x
PEG 3.02x
EV/EBITDA 29.89x
Growth
34 /100
Stable EPS growth 8.43%
Book val. growth 4.58%
Rev. growth 3.08%
Profitability
78 /100
Strong Gross margin 75.38%
FCF margin 24.19%
Net margin 4.78%
Quality
31 /100
Poor ROIC 5.62%
Asset turnover 0.51x
ROE 6.60%
Debt
46 /100
Moderate Debt/Equity 1.29x
Net debt/EBITDA 3.40x
Current ratio 1.32x
Stability
47 /100
Moderate Beta 0.23x
Profitable years 6
Rev. volatility 3.15%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MRK
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert Davis
Employees
74,000
Headquarters
Rahway
Upcoming events
15 SEP
Ex-Dividend
Ex-dividend date
07 OCT
Dividend Payment
Payment date
29 OCT
Earnings
Upcoming earnings report